| POLÁŠKOVÁ, Kristýna, Tomáš MERTA, Alexandra MARTINČEKOVÁ, Danica ZAPLETALOVÁ, Michal KÝR, Pavel MAZÁNEK, Zdenka KŘENOVÁ, Peter MÚDRY, Marta JEŽOVÁ, Jiří TŮMA, Jarmila SKOTÁKOVÁ, Ivana ČERVINKOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ, Hana NOSKOVÁ, Karol PÁL, Ondřej SLABÝ, Pavel FABIAN, Šárka KOZÁKOVÁ, Jakub NERADIL, Renata VESELSKÁ, Veronika KANDEROVÁ, Jiří ŠTARHA, Tomáš FREIBERGER, Giannoula Lakka KLEMENT and Jaroslav ŠTĚRBA. Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside. Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2020, vol. 9, FEB 2020, p. 1-9. ISSN 2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2019.01531. |
Other formats:
BibTeX
LaTeX
RIS
@article{1670461,
author = {Polášková, Kristýna and Merta, Tomáš and Martinčeková, Alexandra and Zapletalová, Danica and Kýr, Michal and Mazánek, Pavel and Křenová, Zdenka and Múdry, Peter and Ježová, Marta and Tůma, Jiří and Skotáková, Jarmila and Červinková, Ivana and Valík, Dalibor and Zdražilová Dubská, Lenka and Nosková, Hana and Pál, Karol and Slabý, Ondřej and Fabian, Pavel and Kozáková, Šárka and Neradil, Jakub and Veselská, Renata and Kanderová, Veronika and Štarha, Jiří and Freiberger, Tomáš and Klement, Giannoula Lakka and Štěrba, Jaroslav},
article_location = {Lausanne},
article_number = {FEB 2020},
doi = {http://dx.doi.org/10.3389/fonc.2019.01531},
keywords = {Burkitt lymphoma; targeted therapy; precision medicine; theranostics; pediatric oncology},
language = {eng},
issn = {2234-943X},
journal = {Frontiers in Oncology},
title = {Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2019.01531/full},
volume = {9},
year = {2020}
}
TY - JOUR
ID - 1670461
AU - Polášková, Kristýna - Merta, Tomáš - Martinčeková, Alexandra - Zapletalová, Danica - Kýr, Michal - Mazánek, Pavel - Křenová, Zdenka - Múdry, Peter - Ježová, Marta - Tůma, Jiří - Skotáková, Jarmila - Červinková, Ivana - Valík, Dalibor - Zdražilová Dubská, Lenka - Nosková, Hana - Pál, Karol - Slabý, Ondřej - Fabian, Pavel - Kozáková, Šárka - Neradil, Jakub - Veselská, Renata - Kanderová, Veronika - Štarha, Jiří - Freiberger, Tomáš - Klement, Giannoula Lakka - Štěrba, Jaroslav
PY - 2020
TI - Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside
JF - Frontiers in Oncology
VL - 9
IS - FEB 2020
SP - 1-9
EP - 1-9
PB - Frontiers Media S.A.
SN - 2234943X
KW - Burkitt lymphoma
KW - targeted therapy
KW - precision medicine
KW - theranostics
KW - pediatric oncology
UR - https://www.frontiersin.org/articles/10.3389/fonc.2019.01531/full
L2 - https://www.frontiersin.org/articles/10.3389/fonc.2019.01531/full
N2 - In order to identify reasons for treatment failures when using targeted therapies, we have analyzed the comprehensive molecular profiles of three relapsed, poor-prognosis Burkitt lymphoma cases. All three cases had resembling clinical presentation and histology and all three patients relapsed, but their outcomes differed significantly. The samples of their tumor tissue were analyzed using whole-exome sequencing, gene expression profiling, phosphoproteomic assays, and single-cell phosphoflow cytometry. These results explain different treatment responses of the three histologically identical but molecularly different tumors. Our findings support a personalized approach for patient with high risk, refractory, and rare diseases and may contribute to personalized and customized treatment efforts for patients with limited treatment options like relapsed/refractory Burkitt lymphoma. The main aim of this study is to analyze three relapsed Burkitt lymphoma patients using a comprehensive molecular profiling, in order to explain their different outcomes and to propose a biomarker-based targeted treatment. In cases 1 and 3, the tumor tissue and the host were analyzed prospectively and appropriate target for the treatment was successfully implemented; however, in case 2, analyses become available only retrospectively and his empirically based rescue treatment did not hit the right target of his disease.
ER -
POLÁŠKOVÁ, Kristýna, Tomáš MERTA, Alexandra MARTINČEKOVÁ, Danica ZAPLETALOVÁ, Michal KÝR, Pavel MAZÁNEK, Zdenka KŘENOVÁ, Peter MÚDRY, Marta JEŽOVÁ, Jiří TŮMA, Jarmila SKOTÁKOVÁ, Ivana ČERVINKOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ, Hana NOSKOVÁ, Karol PÁL, Ondřej SLABÝ, Pavel FABIAN, Šárka KOZÁKOVÁ, Jakub NERADIL, Renata VESELSKÁ, Veronika KANDEROVÁ, Jiří ŠTARHA, Tomáš FREIBERGER, Giannoula Lakka KLEMENT and Jaroslav ŠTĚRBA. Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside. \textit{Frontiers in Oncology}. Lausanne: Frontiers Media S.A., 2020, vol.~9, FEB 2020, p.~1-9. ISSN~2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2019.01531.
|
